Salarius Pharmaceuticals, Inc. (SLRX)

0.4848 -0.0012 (-0.25%) At close: 04:00PM EDT

Salarius Pharmaceuticals, Inc.

2450 Holcombe Boulevard
Suite X
Houston, TX 77021
United States
832 834 6992
https://www.salariuspharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David J. Arthur M.B.A.	CEO, President & Director	729.58k	N/A	1963
Mr. Mark J. Rosenblum CPA	Executive VP of Finance & CFO	409.98k	N/A	1953
Dr. Nadeem Q. Mirza M.D., M.P.H.	Senior Vice President of Clinical Development	N/A	N/A	N/A
Dr. Daniela Y. Santiesteban	Director of Targeted Protein Degradation Program	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.

Corporate governance

Salarius Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.